Apexigen Inc
Change company Symbol lookup
Select an option...
APGN Apexigen Inc
ATAI ATAI Life Sciences NV
FTS Fortis Inc
VLO Valero Energy Corp
BBLN+ Babylon Holdings Equity Warrants 21st Oct 2026 *W EXP 10/21/2026
NEGG Newegg Commerce Inc
LTRY Lottery.com Inc
RCLF Rosecliff Acquisition Corp I
SSYS Stratasys Ltd
GRN iPath? Series B Carbon ETN
Go

Company profile

Apexigen, Inc., formerly Brookline Capital Acquisition Corp., is a clinical-stage biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. It has a diversified pipeline of wholly owned and partnered assets leveraging its APXiMAB antibody discovery platform. The Company’s pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, which is in Phase II clinical development, and also includes several preclinical stage immuno-oncology programs. The Company’s lead asset, sotigalimab, is a CD40 agonist with epitope specificity and Fc receptor engagement for optimal therapeutic effect. Its sotigalimab is used for the treatment of Melanoma (post PD-1), Esophageal/GEJ, Sarcoma, Rectal and Ovarian cancers. Its pipeline also includes APX601 and APX801. It has out-licensed five programs for the development of product candidates that were discovered using the APXiMAB platform.

Price
Delayed
$3.40
Day's Change
-0.07 (-2.02%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.60
Day's Low
3.31
Volume
(Light)

Today's volume of 68,405 shares is on pace to be much lighter than APGN's 10-day average volume of 270,666 shares.

68,405

Earnings information for APGN is not available.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.